This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hennekens, C. H. Articles by Borzak, S. Search for Related Content PubMed PubMed Citation Articles by Hennekens, C. H. Articles by Borzak, S. Social Bookmarking                         What's this?

Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease

Department of Clinical Science and Medical Education & Center of Excellence, Charles E. Schmidt College of Biomedical Science, Florida Atlantic University, Boca Raton, Chenneke{at}fau.edu, Departments of Medicine & Epidemiology and Public Health, Miller School of Medicine, University of Miami, Miami, Department of Preventive Medicine, University College of Medicine

Steven Borzak, MD

E. Schmidt College of Biomedical Science, Florida Atlantic University, Boca Raton, Department of Medicine NOVA Southeastern University College of Medicine, Ft. Lauderdale, Florida

Cyclooxygenase-2 inhibitors relieve pain from inflammatory conditions by decreasing the gastrointestinal side effects from traditional nonsteroidal anti-inflammatory drugs. Basic research provided plausible mechanisms and some observational epidemiological studies, case-control and cohort, indicated that patients prescribed with cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory drugs had increased risks for myocardial infarction and stroke. Because patients prescribed with cyclooxygenase-2 inhibitors were systematically different, uncontrolled and uncontrollable confounding by indication was as large as the observed risks. Thus, epidemiological studies or their meta-analyses could not discern whether, and if so, how much, the risks were real. A comprehensive meta-analysis of randomized trials indicated that cyclooxygenase-2 inhibitors increased the risk of vascular events by 42%, almost exclusively myocardial infarction, as did high-dose regimens of ibuprofen and diclofenac, but not naproxen. Individual clinical judgments and policy decisions should include cardiovascular disease and noncardiovascular disease risks including gastrointestinal side effects and clinical benefits including improved quality of life from less pain and disability.

Key Words: cyclooxygenase-2 inhibitors • nonsteroidal anti-inflammatory drugs • cardiovascular disease

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 13, No. 1, 41-50 (2008)
DOI: 10.1177/1074248407312990


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I. T. Padol and R. H. Hunt Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation Rheumatology, September 24, 2009; (2009) kep225v1. [Abstract] [Full Text] [PDF]